Australian cell medicine company Mesoblast (ASX:MSB) has announced that the US FDA supported an accelerated approval pathway for the company's rexlemestrocel-L. …
Mesoblast says US FDA feedback indicates support for accelerated approval pathway
March 11, 2024 Australian Biotech
Latest Video
New Stories
-
NZ Government appoints former Deputy PM new chair of Pharmac
April 29, 2024 - - Latest News -
The listing will 'benefit thousands of Australian women', says Mark Butler
April 29, 2024 - - Latest News -
'An important first step to achieving reimbursed access for eligible patients in Australia'
April 28, 2024 - - Latest News -
The 'Week in Review' Podcast - 26 April
April 28, 2024 - - Podcast -
New research shows adult vaccination programs deliver major return on investment
April 26, 2024 - - Latest News -
Productivity Commission research backs the benefit of faster access to medicines
April 26, 2024 - - Latest News -
Let's make decisions based on credible information and not guesswork
April 24, 2024 - - Latest News